XNAS
ILMN
Market cap28bUSD
Jul 22, Last price
190.87USD
1D
-0.86%
1Q
52.16%
Jan 2017
53.24%
IPO
901.86%
Name
Illumina Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1998 and headquartered in San Diego, California, Illumina, Inc. delivers cutting-edge sequencing and array technologies crucial for genetic and genomic analysis. The company's comprehensive offerings empower clients across numerous sectors, facilitating the integration of genomic solutions into both research and clinical applications. These span critical fields such as life sciences, oncology, reproductive health, and agriculture. Illumina's product suite encompasses analytical instruments and their associated consumables, complemented by a range of services including genotyping, sequencing, instrument support contracts, development and licensing partnerships, and cancer detection testing. Its extensive customer base comprises genomic research centers, academic bodies, government laboratories, hospitals, pharmaceutical and biotechnology companies, commercial molecular diagnostic labs, and consumer genomics enterprises. The company directly distributes its products across North America, Europe, Latin America, and the Asia-Pacific region, while also leveraging life-science distributors to reach markets in Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑00 | 2021‑00 | 2019‑12 | 2018‑12 | 2018‑12 | 2017‑12 | 2017‑00 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||